Half-year report · Q2
2590.TEDINET S100WMQW
Period2025-01-21 → 2025-07-20
Filed2025-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥117.7bn | 2025-01-21 → 2025-07-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.6bn | 2024-01-21 → 2024-07-20 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-21 → 2024-07-20 | Cons. | Operating income |
| Ordinary income | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2024-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥6.5bn | 2024-01-21 → 2024-07-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.9bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss |
| Net income | ¥4.7bn | 2024-01-21 → 2024-07-20 | Cons. | Profit loss |
| Total assets | ¥196.2bn | at 2025-07-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥200.3bn | at 2024-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.5bn | at 2025-07-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥90.7bn | at 2025-07-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥94.2bn | at 2024-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2025-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.9bn | at 2025-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥36.3bn | at 2024-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.1bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.5bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.2bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.1bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2024-01-21 → 2024-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-43.05 | 2025-01-21 → 2025-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥155.36 | 2024-01-21 → 2024-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.1% | at 2024-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2025-07-20 | −¥506m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥65m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥2.0bn |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥263m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥184m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥530m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥3.1bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥7.0bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥6.8bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥158m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥463m |
| —segment total | revenue | 2025-01-21 → 2025-07-20 | ¥117.9bn |
| —segment total | revenue external | 2025-01-21 → 2025-07-20 | ¥117.7bn |
| —segment total | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥228m |
| —segment total | segment profit | 2025-01-21 → 2025-07-20 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2024-07-20 | −¥167m |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2024-07-20 | −¥674m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥73.0bn |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥17m |
| jpcrp040300-q2r_E00424-000Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥238m |
| jpcrp040300-q2r_E00424-000Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2024-07-20 | −¥295m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥11.1bn |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥3m |
| jpcrp040300-q2r_E00424-000Food Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥899m |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥26.8bn |
| jpcrp040300-q2r_E00424-000International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥2.3bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2024-07-20 | ¥6.9bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2024-07-20 | ¥6.7bn |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥146m |
| jpcrp040300-q2r_E00424-000Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2024-07-20 | ¥324m |
| —segment total | revenue | 2024-01-21 → 2024-07-20 | ¥117.7bn |
| —segment total | revenue external | 2024-01-21 → 2024-07-20 | ¥117.6bn |
| —segment total | revenue intersegment | 2024-01-21 → 2024-07-20 | ¥167m |
| —segment total | segment profit | 2024-01-21 → 2024-07-20 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YTDDuration | 75000000 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | 84000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 1810000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1562000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | -601000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -1204000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 2589000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -3712000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 33713000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 29642000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 36302000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 25930000000 | JPY |
| Promotion expenses sga | Prior1YTDDuration | 12706000000 | JPY |
| Promotion expenses sga | CurrentYTDDuration | 12818000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 1495000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 1465000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 300000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 277000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 72992000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 26757000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6726000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 11102000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 117578000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 117578000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 17000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 146000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 167000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -167000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | 73009000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 26757000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 6872000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 11106000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 117745000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -167000000 | JPY |
| Net sales | Prior1YTDDuration | 117578000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DomesticBeverageBusinessReportableSegmentsMember | -238000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000InternationalBeverageBusinessReportableSegmentsMember | 2267000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000PharmaceuticalRelatedBusinessReportableSegmentsMember | 324000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000FoodBusinessReportableSegmentsMember | 899000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00424-000DyDoPharmaReportableSegmentsMember | -295000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |